Suraksha Diagnostic Ltd

- The company has a fairly underleveraged balance sheet. - Currently, all expansions and activities are being funded through internal accruals. - If required in the future, the company can always raise debt for growth. - No specific mention of any ongoing or planned equity fundraising was noted. - The company is actively looking for inorganic growth opportunities, which could potentially require funding.

- The company plans to invest around INR 70 crores annually in opening new centers organically. - For FY26, they plan to add 12 to 15 new centers (5 big and 13 small centers in progress). - They have a fairly underleveraged balance sheet and can raise debt if needed, but currently, expansions are funded through internal accruals. - They are actively looking for inorganic growth opportunities through acquisitions, especially in new geographies with existing players. - The genomic lab setup is a key strategic investment aimed at increasing B2B business, without long-term margin impact. - They are developing software for loyalty schemes to incentivize repeat tests, to be operational in about two more quarters.

- Suraksha Diagnostic Limited expects a consistent revenue growth of around 15% year-on-year for the next 2 to 3 years. - The number of tests and patient volumes are projected to grow, supported by new center additions (12 to 15 own centers plus PPP and Fetomat centers adding up to 18-20 total). - New centers contribute gradually with initial revenues around INR 90 lakhs for small centers and INR 1.5-2 crores for big centers in the first year. - Despite some quarter-to-quarter impacts (e.g., floods, delayed licenses), mature centers grow at approximately 10%. - The company anticipates margin expansion with EBITDA margin increasing by 1-2% annually due to operating leverage as new centers mature. - Growth is supported by scaling B2B business and genomic services with no negative long-term margin impact expected. - Market penetration in current and new geographies, including untapped regions like Northeast India, will fuel future growth.

- Suraksha Diagnostic Limited expects a top-line revenue growth of around 15% year-on-year over the next 2 to 3 years. - EBITDA margins are projected to increase by 1% to 2% annually as the company benefits from scale and tighter cost control. - PAT (Profit After Tax) margins are also expected to improve by 1% to 2% each year. - Newer centers currently impact margins negatively but are expected to reach breakeven and contribute to improved overall profitability. - The company maintains a conservative growth approach but anticipates margin expansion driven by mature centers and operating leverage. - EPS showed improvement from INR3.43 in H1 FY25 to INR3.53 in H1 FY26, with expectations for continued growth aligned with revenue and margin improvement.

The transcript provided from Suraksha Diagnostic Limited's earnings call does not explicitly mention any details about the company's current or expected order book or pending orders. The discussion mainly focuses on: - Revenue growth and financial performance. - Expansion plans with new center openings. - B2B and B2C mix. - Impact of external factors like floods and rain. - Strategies for inorganic growth and acquisitions. - Genomics business and service offerings. Therefore, no specific information on order book or pending orders is disclosed in the given transcript.